Working… Menu

LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03090659
Recruitment Status : Enrolling by invitation
First Posted : March 27, 2017
Last Update Posted : August 14, 2019
Second Affiliated Hospital of Xi'an Jiaotong University
Ruijin Hospital
Jiangsu Provincial People's Hospital
Shanghai Changzheng Hospital
Information provided by (Responsible Party):
Nanjing Legend Biotech Co.